Compare Domino's Pizza, Inc. (DPZ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Tango Therapeutics Inc. — how do they compare? Domino's Pizza, Inc. trades at $294.5 (market cap $9.74B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Domino's Pizza, Inc. is far larger — about 2.6× Tango Therapeutics Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.69% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Tango Therapeutics Inc. for 0 Days on average.
| DPZ | TNGX | |
|---|---|---|
Market Cap | $9.74B | $3.75B |
Volume | 2,053,142 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $32.90 |
52-Week Low | $282.89 | $7.50 |
Typical Hold Time | 106 Days | 0 Days |
Enterprise Value | $14.63B | $2.77B |
Dividend Yield | 2.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $295.89, down 4.83% with mixed technical signals but strong fundamentals. The stock shows a bullish overall technical signal despite recent price weakness, while fundamentals reveal consistent revenue growth to $4.94 billion in 2025 and healthy net margins of 11.86%. Recent earnings show improvement with a Q3 2026 beat after three consecutive misses, though the company faces high debt levels and flat dividend growth.
The outlook remains cautiously optimistic with a $368 consensus price target representing 24% upside potential. Key opportunities include sustained profitability and market leadership, while risks center on high leverage and competitive pressures. Analyst sentiment leans bullish with 50% buy ratings, but investors should monitor debt management and same-store sales trends.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
